PDZD11

Across TCGA pan-cancer cohorts, PDZD11 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PDZD11 data layer compared with 30 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PDZD11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PDZD11 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where PDZD11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	1.000	0.600	.008	17	view →
LSCC	DFS	Median	III,IV	1.000	0.612	.003	15	view →
PDAC	DFS	Median	All	0.838	0.685	.005	15	view →
GBM	OS	Quartile	All	0.798	0.986	.005	7	view →
UCEC	DFS	Tertile	All	0.917	0.739	.036	2	view →
HNSC	DFS	Median	All	0.977	0.927	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PDZD11–CCRCC (DFS)

Open the CCRCC breakdown →